These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 27492719)

  • 1. Identification of Limonol Derivatives as Heat Shock Protein 90 (Hsp90) Inhibitors through a Multidisciplinary Approach.
    Chini MG; Malafronte N; Vaccaro MC; Gualtieri MJ; Vassallo A; Vasaturo M; Castellano S; Milite C; Leone A; Bifulco G; De Tommasi N; Dal Piaz F
    Chemistry; 2016 Sep; 22(37):13236-50. PubMed ID: 27492719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A chemical-biological study reveals C9-type iridoids as novel heat shock protein 90 (Hsp90) inhibitors.
    Dal Piaz F; Vassallo A; Temraz A; Cotugno R; Belisario MA; Bifulco G; Chini MG; Pisano C; De Tommasi N; Braca A
    J Med Chem; 2013 Feb; 56(4):1583-95. PubMed ID: 23362862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural characterization of tetranortriterpenes from Pseudrocedrela kotschyi and Trichilia emetica and study of their activity towards the chaperone Hsp90.
    Piaz FD; Malafronte N; Romano A; Gallotta D; Belisario MA; Bifulco G; Gualtieri MJ; Sanogo R; Tommasi ND; Pisano C
    Phytochemistry; 2012 Mar; 75():78-89. PubMed ID: 22226245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
    Wang L; Li L; Zhou ZH; Jiang ZY; You QD; Xu XL
    Eur J Med Chem; 2017 Aug; 136():63-73. PubMed ID: 28482218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors.
    Zhao H; Garg G; Zhao J; Moroni E; Girgis A; Franco LS; Singh S; Colombo G; Blagg BS
    Eur J Med Chem; 2015 Jan; 89():442-66. PubMed ID: 25462258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of pyrimidinyl acyl thioureas as novel Hsp90 inhibitors in invasive ductal breast cancer and its bone metastasis.
    Koca İ; Özgür A; Er M; Gümüş M; Açikalin Coşkun K; Tutar Y
    Eur J Med Chem; 2016 Oct; 122():280-290. PubMed ID: 27376491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
    Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
    J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hsp90 inhibitors and drugs from fragment and virtual screening.
    Roughley S; Wright L; Brough P; Massey A; Hubbard RE
    Top Curr Chem; 2012; 317():61-82. PubMed ID: 21647838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity.
    Rowlands MG; Newbatt YM; Prodromou C; Pearl LH; Workman P; Aherne W
    Anal Biochem; 2004 Apr; 327(2):176-83. PubMed ID: 15051534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the plant compound geraniin as a novel Hsp90 inhibitor.
    Vassallo A; Vaccaro MC; De Tommasi N; Dal Piaz F; Leone A
    PLoS One; 2013; 8(9):e74266. PubMed ID: 24066128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and pharmacological evaluation of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-N-arylmethyl-1,2,3,4-tetrahydro-3-isoquinolinecarboxamides as potent Hsp90 inhibitors.
    Liang C; Wu X; Li Z; Zhu J; Lu C; Shen Y
    Eur J Med Chem; 2018 Jan; 143():85-96. PubMed ID: 29172085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule inhibitors targeting heat shock protein 90: An updated review.
    Li Y; Dong J; Qin JJ
    Eur J Med Chem; 2024 Sep; 275():116562. PubMed ID: 38865742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular docking study, synthesis and biological evaluation of Mannich bases as Hsp90 inhibitors.
    Dutta Gupta S; Bommaka MK; Mazaira GI; Galigniana MD; Subrahmanyam CV; Gowrishankar NL; Raghavendra NM
    Int J Biol Macromol; 2015 Sep; 80():253-9. PubMed ID: 26116388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of New Hsp90 Inhibitors: Structure Based Virtual Screening, Molecular Dynamic Simulation, Synthesis and Biological Evaluation.
    Abbasi M; Amanlou M; Aghaei M; Hassanzadeh F; Sadeghi-Aliabadi H
    Anticancer Agents Med Chem; 2021; 21(18):2583-2591. PubMed ID: 33563187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
    Hall JA; Seedarala S; Rice N; Kopel L; Halaweish F; Blagg BS
    J Nat Prod; 2015 Apr; 78(4):873-9. PubMed ID: 25756299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.
    Vallée F; Carrez C; Pilorge F; Dupuy A; Parent A; Bertin L; Thompson F; Ferrari P; Fassy F; Lamberton A; Thomas A; Arrebola R; Guerif S; Rohaut A; Certal V; Ruxer JM; Gouyon T; Delorme C; Jouanen A; Dumas J; Grépin C; Combeau C; Goulaouic H; Dereu N; Mikol V; Mailliet P; Minoux H
    J Med Chem; 2011 Oct; 54(20):7206-19. PubMed ID: 21972823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
    Miura T; Fukami TA; Hasegawa K; Ono N; Suda A; Shindo H; Yoon DO; Kim SJ; Na YJ; Aoki Y; Shimma N; Tsukuda T; Shiratori Y
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5778-83. PubMed ID: 21875802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of N-pyridoyl-Δ
    Kadasi S; Yerroju R; Gaddam S; Pullanagiri N; Chary M; Pingili D; Raj S; Raghavendra NM
    Arch Pharm (Weinheim); 2020 Feb; 353(2):e1900192. PubMed ID: 31808979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
    Arodola OA; Soliman ME
    Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors.
    Park SY; Oh YJ; Lho Y; Jeong JH; Liu KH; Song J; Kim SH; Ha E; Seo YH
    Eur J Med Chem; 2018 Jan; 143():390-401. PubMed ID: 29202402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.